Amgen
Amgen scraps pancreatic cancer drug
August 9, 2012Research and Development, Sales and Marketing Amgen, GAMMA, Ganitumab, pancreatic
Biotech company Amgen has abandoned its late-stage trial of a new drug for one of the most hard-to-treat of all …
Lipitor fallout prompts Pfizer to cut Irish workforce
June 7, 2012Manufacturing and Production Amgen, Ireland, Lipitor, Pfizer, cuts, patent loss
Falling demand for blockbuster cholesterol drug Lipitor has prompted Pfizer to cut staff levels at two manufacturing facilities in Ireland. …
Sanofi/Regeneron cholesterol drug reaches Phase III
May 29, 2012Research and Development, Sales and Marketing Amgen, PCKS9, Regeneron, SAR236553, Sanofi
Sanofi and Regeneron’s anti-cholesterol drug has impressed in a mid-stage trial, and will now progress into Phase III. The firms’ …
Amgen to acquire kidney disease specialist for $315m
April 11, 2012Sales and Marketing Amgen, KAI Pharmaceuticals
Amgen will acquire KAI Pharmaceuticals for $315 million to bolster its late-stage pipeline. The deal, which should be completed within …
AstraZeneca signs respiratory pact with Amgen
April 5, 2012Research and Development Amgen, AstraZeneca, MedImmune, respiratory
AstraZeneca has bought its way into Amgen’s inflammation portfolio with a $50 million upfront payment to co-develop and commercialise five …
NICE recommends Xgeva for bone metastasis
March 29, 2012Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer
NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …
Approval for Affymax and Takeda’s anaemia treatment
March 29, 2012Sales and Marketing Affymax, Amgen, ESA, Epogen, Takeda, omontys
The first rival treatment to Amgen’s portfolio of anaemia drugs has been approved in the US.Omontys (peginesatide) has been developed …
Sanofi sets up cholesterol drug showdown with Amgen
March 27, 2012Research and Development, Sales and Marketing Amgen, BMS, LDL, Lipitor, Merck, Regeneron, Sanofi
Sanofi and Amgen have posted results for their new injectable cholesterol drugs within 24 hours of each other. Both drugs …
Novartis starts late-stage biosimilar trials for Amgen drugs
January 19, 2012Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis
Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …
Amgen’s chief executive and chairman Kevin Sharer to retire
December 16, 2011Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Amgen
Kevin Sharer, Amgen’s chairman and chief executive, has announced his retirement next year, leading the way for Robert Bradway to …
Amgen poaches Tony Hooper from Bristol-Myers Squibb
October 21, 2011Medical Communications Amgen, BMS
Amgen has appointed Tony Hooper as the new executive vice president of global commercial operations. Hooper, 56, joins Amgen after …
Amgen bone cancer drug Xgeva approved in Europe
July 18, 2011Sales and Marketing Amgen, Prolia, Xgeva, denosumab
Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …
Amgen collaborates on cancer antibody research
July 13, 2011Research and Development Amgen, Cancer, TGF-beta monoclonal antibody, research and development news
Amgen has teamed up with German biotech Micromet to develop tumour-destroying antibodies in a two-year deal that could net Micromet …
UCB and Amgen’s osteoporosis drug shows promise
April 21, 2011Research and Development Amgen, UCB, osteoporosis
Amgen and UCB have announced strong results from a phase II study of their new postmenopausal osteoporosis treatment. Most existing …
Amgen’s novel lung cancer drug disappoints in phase III
April 1, 2011Research and Development Amgen, Millennium, NSCLC, Takeda, motesanib, non-small cell lung cancer
Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
